Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkae014 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Lauren E Higdon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Biomarker and Discovery Research, Immune Tolerance Network, San Francisco, CA, United States. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Receptors, Immunologic, Programmed Cell Death 1 Receptor, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, Immune Tolerance Network.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity. We characterized T cell responses by flow cytometry and identified an exhausted-like population of CD2low CD4 effector memory T cells coexpressing TIGIT and PD1 that expanded by 11 wk after the start of treatment. This population was not entirely spared from alefacept-mediated depletion in vivo or in vitro but recovered through homeostatic proliferation of CD2low cells in vivo. Proliferation of TIGIT+PD1+ effector memory CD4 T cells increased with treatment, with a concomitant reduction of proinflammatory cytokine production. The persistent increase of TIGIT+PD1+ effector memory CD4 T cells was specific to alefacept treatment; 2 other T cell depleting therapies, teplizumab and anti-thymocyte globulin, induced only a transient increase in this CD4 population. Our data suggest that the expanding TIGIT+PD1+ effector memory CD4 T cell population represents a promising biomarker of early treatment effects of alefacept. The nondepleting effects on proliferation and cytokine production also suggest agonistic activity by this CD2 targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomarker and Discovery Research, Immune Tolerance Network, San Francisco, CA, United States.
- Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
- Diabetes Center, University of California, San Francisco, San Francisco, CA, United States.
ORCID-Profile: Lauren E Higdon, Laura A Cooney, Elisavet Serti, Duangchan Suwannasaen, Virginia S Muir, Alice E Wiedeman, Kristina M Harris, Jorge Pardo, Mark S Anderson, Cate Speake, Gerald T Nepom, Peter S Linsley, Srinath Sanda, S Alice Long
Förderung
- NIAID NIH HHS
- NIH HHS
- Immune Tolerance Network
- NIDDK NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health
Zitieren
APA
Higdon, L. E., Cooney, L. A., Serti, E., Suwannasaen, D., Muir, V. S., Wiedeman, A. E., Harris, K. M., Pardo, J., Anderson, M. S., Speake, C., Nepom, G. T., Linsley, P. S., Sanda, S., & Long, S. A. (2025). Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkae014
Vancouver
Higdon LE, Cooney LA, Serti E, Suwannasaen D, Muir VS, Wiedeman AE, et al. Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkae014
BibTeX
@article{Higdon2025,
author = {Higdon, Lauren E and Cooney, Laura A and Serti, Elisavet and Suwannasaen, Duangchan and Muir, Virginia S and Wiedeman, Alice E and Harris, Kristina M and Pardo, Jorge and Anderson, Mark S and Speake, Cate and Nepom, Gerald T and Linsley, Peter S and Sanda, Srinath and Long, S Alice},
title = {Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkae014}
}
EUVIMED